PLANNED CONSULTATION AREAS
Care starts
with understanding.
These are the treatment areas we intend to explore with our clinical team. Final services depend on provider arrangements, clinical standards, and applicable requirements.
Medical support for eligible adultsGLP-1 weight management
A planned consultation pathway to discuss prescription weight management, including GLP-1–based medicines when appropriate. A licensed prescriber will assess medical eligibility, medication risks, and follow-up needs. Nutrition and training remain part of the bigger picture.
Specific medicines, availability, and pricing will be confirmed before launch.
Evaluation before treatmentTestosterone replacement therapy
A planned pathway for men with concerns about low testosterone. Symptoms alone do not diagnose a deficiency: evaluation includes appropriate laboratory testing and consistently low testosterone levels. If indicated, a prescriber can discuss TRT, alternatives, risks, fertility considerations, and monitoring.
TRT is not a guaranteed treatment or a general performance enhancement service.
An individual clinical conversationHormone health & balancing
A planned consultation pathway for hormone concerns, including symptoms around perimenopause and menopause. “Hormone balancing” starts with understanding symptoms and medical history. A clinician may discuss hormonal or nonhormonal options after weighing benefits and risks.
Not everyone needs hormone therapy. Menopause hormone medicines carry risks, including blood clots and certain cancers, that must be considered individually.
Evidence and appropriateness firstPeptide consultations
We plan to include clinician-led discussions of peptide-based prescription options where medically appropriate and legally available. Peptides are a broad category; an approved medicine for one indication does not validate every peptide marketed for wellness.
Specific peptide offerings are not confirmed. Many wellness peptides are not FDA-approved and have limited human safety data; this page does not promise access to unapproved or research-only products.